Bristol-Myers Squibb Co. is taking out a $33.5 billion loan to help finance its purchase of Celgene Corp. in the largest ever pharmaceutical-company acquisition.
The loan will contribute to the $74 billion cash-and-stock deal and be refinanced with $32 billion of new debt, according to filings on Thursday. It will rank as the seventh-largest bridge facility on record, according to data compiled by Bloomberg. Morgan Stanley and MUFG Bank Ltd. are underwriting the financing.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
- Exclusive discounts on ALM and Treasury & Risk events.
- Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
*May exclude premium content
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
